RxDoctor Payments Data

Miguel Sagardia, MD

Internal Medicine · Greensboro, NCNPI 1053390641

Payments from drug & device makers

$6,285in general payments, 2019–2025

Across 353 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$697
  • AstraZeneca$582
  • Lilly USA, LLC$480
  • AbbVie$366
  • GSK$363
  • Daiichi Sankyo Inc.$311
  • plus $3K from 41 others

What the payments were for

  • Food & beverage$6,285100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,285 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$48,568
Medicare patients
139
Services billed
835

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide70$106,382
FarxigaDapagliflozin Propanediol79$88,253
JardianceEmpagliflozin44$61,256
MounjaroTirzepatide19$46,906
Trelegy ElliptaFluticasone/Umeclidin/Vilanter68$44,228
OzempicSemaglutide37$35,051
Breztri AerosphereBudesonide/Glycopyr/Formoterol36$28,206
JanuviaSitagliptin Phosphate23$28,049
RybelsusSemaglutide11$26,522
EliquisApixaban19$13,309
Tresiba Flextouch U-100Insulin Degludec28$11,617
Rosuvastatin Calcium470$6,045
Breo ElliptaFluticasone/Vilanterol15$5,854
Atorvastatin Calcium224$2,407
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide72$2,278

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$480$153,28789 claims
AstraZenecaFarxiga, Breztri Aerosphere$582$116,459115 claims
Novo NordiskOzempic, Rybelsus$697$61,57348 claims
Boehringer IngelheimJardiance$286$61,25644 claims
GSKTrelegy Ellipta, Breo Ellipta$363$50,08283 claims
MerckJanuvia$68$28,04923 claims
PfizerEliquis$245$13,30919 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$51$1,229105 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →